ARS Wealth Advisors Group LLC Trims Stock Holdings in Pfizer Inc. (NYSE:PFE)

ARS Wealth Advisors Group LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 2.9% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 24,239 shares of the biopharmaceutical company’s stock after selling 728 shares during the period. ARS Wealth Advisors Group LLC’s holdings in Pfizer were worth $614,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Miracle Mile Advisors LLC boosted its holdings in Pfizer by 6.2% in the first quarter. Miracle Mile Advisors LLC now owns 233,234 shares of the biopharmaceutical company’s stock valued at $5,910,000 after purchasing an additional 13,534 shares during the last quarter. RDA Financial Network boosted its holdings in Pfizer by 5.5% in the first quarter. RDA Financial Network now owns 68,585 shares of the biopharmaceutical company’s stock valued at $1,738,000 after purchasing an additional 3,591 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in Pfizer by 41.3% in the first quarter. Sivia Capital Partners LLC now owns 14,624 shares of the biopharmaceutical company’s stock valued at $371,000 after purchasing an additional 4,271 shares during the last quarter. Persium Advisors LLC purchased a new position in Pfizer in the first quarter valued at about $495,000. Finally, Impact Capital Partners LLC boosted its holdings in Pfizer by 26.5% in the first quarter. Impact Capital Partners LLC now owns 13,686 shares of the biopharmaceutical company’s stock valued at $347,000 after purchasing an additional 2,864 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.0%

Shares of Pfizer stock opened at $23.36 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business’s 50 day simple moving average is $22.95 and its 200-day simple moving average is $25.00. The stock has a market capitalization of $132.81 billion, a price-to-earnings ratio of 16.57, a PEG ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was down 7.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.82 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.36%. The ex-dividend date is Friday, May 9th. Pfizer’s payout ratio is 124.64%.

Analyst Ratings Changes

PFE has been the subject of a number of analyst reports. Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.